Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 20/20 | 0.45 |
| ▸ | MAOA | P21397 | 12/20 | 0.45 |
| ▸ | MAOB | P27338 | 12/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102402 | 0.86 | ALDH2 (0.43) | ALDH2MAOAMAOB | |
| SCHEMBL2107674 | 0.80 | ALDH2 (0.56) | ALDH2MAOAMAOB | |
| SCHEMBL4094968 | 0.74 | ALDH2 (0.55) | ALDH2MAOAMAOB | |
| SCHEMBL2107502 | 0.73 | MAPT (0.45) | ALDH2MAOAMAOB | |
| SCHEMBL4096021 | 0.73 | FFAR1 (0.57) | ALDH2MAOAMAOB | |
| SCHEMBL2108695 | 0.73 | FFAR1 (0.55) | ALDH2MAOAMAOB | |
| SCHEMBL4095131 | 0.72 | ALDH2 (0.49) | ALDH2MAOAMAOB | |
| SCHEMBL4101481 | 0.71 | ALDH2 (0.59) | ALDH2MAOAMAOB | |
| SCHEMBL2107513 | 0.70 | ALDH2 (0.56) | ALDH2MAOAMAOB | |
| SCHEMBL2107217 | 0.69 | ALDH2 (0.66) | ALDH2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAOA 62/4885MAOB 47/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 4/4885MAOA 62/4885MAOB 45/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ALDH2 1/4885MAOA 59/4885MAOB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.